1.
Eksp Klin Farmakol
; 79(4): 3-7, 2016 Aug.
Artigo
em Inglês, Russo
| MEDLINE
| ID: mdl-29949696
RESUMO
Primary neuroprotective properties of new inhibitor of Naâº/⺠exchanger (compound RU-1355) were established on the model of 60-min focal ischemia of the left middle cerebral artery followed by 24-h reperfusion in rats. Compound RU-1355 significantly (by 34%) decreased neurological symptoms, reduced (1.67 times) the growth of neuron-specific enolase level in serum, decreased (2.3 times) the size of the necrotic zone, and reduced by 59% (p <0.05) the degree of cerebral edema According to the results of morphometric, immunoassay, and neurological assessments of brain damage, compound RU-1355 is superior on ave- rage by 43.5% (p < 0.05) in comparison to selective NHE1 inhibitor zoniporide.